INTRODUCTION
Variability in drug response to many therapeutic drug classes is well recognized. These interpatient differences have been seen for both drug efficacy and adverse effects. Pharmacogenomics (Pgx) aims to characterize the contribution of genetic polymorphisms to this variability in drug response and toxicity. 1 One promise of Pgx is the application of genotype-guided therapy to maximize the likelihood of drug benefit, while minimizing the likelihood of harmful effects. 2 As such, Pgx-based approaches to patient care might improve pharmacotherapy through more rational drug choices. These therapeutic decisions would be aimed at increasing the benefit-risk ratio of a given drug exposure, based on patient-specific genetic information.
A potential method for incorporating Pgx into therapeutic risk management is to include Pgx information in prescribing information widely available to health care providers. We systematically analyzed the Pgx data in prescribing information available to practitioners (drug package inserts (PIs) from the Physician's Desk Reference (PDR)). Among other criteria, Pgx information was considered sufficient to guide therapy if a genetic or molecular test result determined drug indication or contraindication, altered drug dosing, or increased the risk for adverse drug reactions or treatment failure (see Materials and Methods). In addition, we determined whether practical assays that could facilitate genotyping of patients to guide therapy exist.
RESULTS
The electronic database contained 3382 PIs, which were searched with the keywords outlined in Materials and Methods. After deletion of duplicate results, the initial keyword search yielded 215 PIs. Initial abstracting of these 215 PIs revealed that only 76 (35.3%) contained Pgx data. Information not considered Pgx data in the remaining PIs included descriptions of manufacturing processes through recombinant genetic technology, familial bases of disease for a particular clinical phenotype in which the drug is indicated, and data on human toxicology and mutagenesis. Pgx data were found in PIs for the following drug classes in rank order: anti-infectives, psychotropics, gastrointestinal agents, cardiovascular agents and neurological agents, analgesics and antineoplastics, as well as other drug classes with lower frequency (Table 1) . The majority of drugs within the antiinfective class were antivirals (95.7%). In addition, of the psychotropic drugs, 60% were antidepressants and 33% were antipsychotics. Cardiovascular drugs included antihypertensives, antiarrhythmics, and lipid-lowering agents in equal proportions. Finally, neurological agents were largely comprised of anticonvulsants (71.4%).
With respect to the nature of the Pgx data, the gene involved usually coded for a drug-metabolizing enzyme (52.6%). The remaining 47.4% of Pgx data contained information largely related to variability in viral genomes as predictors of response to antiviral Specific dose recommendations based on genotype were available in the PIs for peg-interferon alpha-2a and ribavirin, both for the treatment of hepatitis C based on viral genotype. The likelihood for successful treatment predicated on a genetic test, that is, indication for a drug in a specific genetic or molecular subgroup, was found in the following five PIs. Alpha 1 -proteinase inhibitor (Prolastin) is not indicated in patients with the PiMS or PiMZ alpha 1 -antitrypsin deficiency phenotypes. Trastuzumab is indicated only in patients with overexpression of the HER2 protein, while tretinoin is indicated in a specific subset of acute myelogenous leukemia patients. Imatinib is indicated in patients with Philadelphia chromosomepositive chronic myeloid leukemia or CD117-positive gastrointestinal stromal tumors. Somatotropin therapy is indicated for patients with growth failure due to Prader-Willi syndrome.
Information on increased risk for potentially life-threatening adverse drug reactions or treatment failure, with conditional recommendations for genetic evaluation, was found for four drugs (recombinant factor IX, somatotropin, divalproex sodium, and valproic acid). Only one of the 25 PIs, for thioridazine, states specific contraindication in a genetic subgroup. Owing to an increased risk for QTc interval prolongation and ventricular arrhythmia, CYP2D6 poor metabolizers (7-8% of Caucasians) should not receive this drug. However, the PI for thioridazine does not explicitly recommend a genetic test for CYP2D6 activity to establish contraindication.
General precautionary statements and/or the need for dose reductions (without specific recommendations) based on drug-metabolizing phenotype were found in the prescribing information for the following drugs: aripiprazole, atomoxetine, celecoxib, mercaptopurine, modafinil, and theophylline. Interestingly, eight PIs (32%) explicitly state or implicitly suggest that no dose changes are necessary based on CYP enzyme phenotypes ( Table 2) .
Of note, a review of the Pgx literature indicates that molecular diagnostics are available for all drugs described in the 25 PIs that contain treatmentguiding Pgx information.
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DISCUSSION
Both clinical pharmacy and medical practice attempt to provide maximally beneficial drug therapy to patients with myriad clinical syndromes and diseases. It is well recognized that interpatient variability in both drug effectiveness and toxicity exists. In fact, the common relationship between drug dose and effectiveness/ toxicity for an individual is unpredictable. As such, clinicians attempt to use patient-specific information (eg, anthropometric and liver and kidney function measures) to guide therapy.
Patient-specific variability in genes that encode drug metabolism, transport, and cellular target proteins is also a source for variability in drug response. 24 It follows, then, that genetic information may be used to tailor drug therapy for a given individual in order to maximize therapeutic benefit while minimizing risks of drug exposure. 25 Pharmacogenomics might be incorporated into clinical practice through systematic education of physicians, pharmacists, and other health care practitioners. Fostering awareness of genetic relationships to drug response in the medical community will be challenging. One strategy for incorporating Pgx into risk management and clinical practice is to include Pgx data in drug PIs and other forms of prescribing information available to practitioners. However, our analysis suggests that, while Pgx-related data 
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I Zineh et al are available for a number of approved drugs, this number is quite small. In addition, we generally found the Pgx data in PIs to be inadequate to guide drug therapy decisions. For example, specific dosing information based on genotype was found for only two drugs. Furthermore, the majority of genetic information was available for drugs that are not commonly prescribed (82% were not in the top 200 drugs of 2002). It should be noted, however, that PIs contain evidencebased, factual data important in patient care. These data are derived from pre-clinical and clinical studies to establish safety and efficacy on a population basis. Such studies were undoubtedly conducted for these purposes and not to establish the value of a molecular testing-based approach to improving outcomes. In addition, there are not many robust, consistently reproducible examples of genetic associations with drug response or toxicity. As such, the lack of usable Pgx information in PIs might be a reflection of the paucity of such data.
As it stands, PIs generally do not contain useful information for genomics-guided pharmacotherapy. Perhaps as more Pgx data become available through voluntary data submission as outlined by the FDA, PIs will contain more informative patientspecific pharmacotherapy recommendations. 26 However, recognizing that the Pgx data submitted to the FDA would largely be exploratory and employ, as of yet, nonvalidated biomarkers, these voluntary data are unlikely to dramatically alter current drug labeling. Rather, informative data to be used clinically are more likely to come from well-designed, reproducible studies.
To highlight the deficiency in useful prescribing information, we consider the example of mercaptopurine. Mercaptopurine (and other thioguanines) is commonly used to treat certain forms of leukemia and rheumatological conditions. In a subset of patients who are deficient in the thiopurine S-methyltransferase (TPMT) enzyme, dose reductions of mercaptopurine may be necessary to avoid thioguanine-induced marrow toxicity and death. 27 In fact, high-volume cancer centers routinely genotype patients for TPMT polymorphisms and dose patients using genotype-specific dosing algorithms, with intermediate and poor metabolizers receiving 65% and 5-10% of standard thioguanine doses, respectively. 28, 29 While pharmacogenomic data exist in the PI for mecaptopurine to inform treatment decisions, we found insufficient data to specifically tailor drug dosing based on TPMT genotype, despite the validity of this biomarker in guiding therapy. 30 It should be recognized, however, that TPMT genotyping is not predictive for many cases in so much as partial TPMT activity does not always mandate reduced doses, and full TPMT activity does not preclude possible myelotoxicity. In fact, the FDA has found insufficient evidence to recommend routine dose adjustment based on TPMT genotyping. 31 Another notable omission from our search includes warfarin, where genetic variability in the CYP2C9 isoenzyme is associated with variable dose requirements and bleeding risks. [32] [33] [34] However, as in the case of TPMT, the usefulness of routine genotype determination over current clinical monitoring methods to guide dosing remains to be determined. 35, 36 As such, the omission of warfarin from our findings may be consistent with the conflicting nature of the Pgx data regarding warfarin therapy.
Perhaps the small number of PIs containing usable Pgx information reflects the relative newness of the field. In addition, while polymorphisms in single genes may contribute to drug response variability (eg, in the case of metabolizing enzyme gene polymorphisms and area under the plasma concentration-time curve), it is more likely that multiple genes involved in both pharmacokinetics and pharmacodynamics together influence the net observed benefit and/ or risk in a given patient. Therefore, a true genomic approach to patient care may represent the most rational paradigm, yet this information is generally not yet available. Of note, while our data suggest that the majority of prescribing information relates to drug-metabolizing enzyme genes, 47.4% of the data implicated genes unrelated to drug pharmacokinetics. This highlights the diversity of Pgx and its potential usefulness beyond the characterization of pharmacokinetic phenotypes.
It is important to note that molecular biology techniques to facilitate genotyping or phenotyping are available for all PIs that contained Pgxguided treatment information. As such, technology exists for broad pharmacogenomics application to patient care. 37 However, these assays have been developed largely in academia, and many of these laboratorybased techniques are time consuming. Furthermore, while these tests are often developed in CLIA-certified academic or commercial laboratories, standardization of these techniques across laboratories may be an issue. [38] [39] [40] This highlights the need to validate laboratory techniques and standardize assays in order to be able to routinely and appropriately employ Pgx in patient care.
As Pgx data continue to emerge and become validated by the scientific and medical communities, several points must be considered including whether or not Pgx-guided therapy improves outcomes over routine care; the relevance of Pgx in chronic disease with drugs that have wide therapeutic indices (ie, the clear majority of the top 200 prescribed drugs); the clear translation of genetically-guided prescribing information such as that found in PIs into practical recommendations for individualization of therapy; and the logistical ease with which Pgx information can be used. In addition, the usefulness of a pharmacogenetic test in the decision analysis process is largely dependent on its test performance characteristics (eg, sensitivity and specificity). Furthermore, as has been previously highlighted, the availability of alternative, validated biomarkers (ie, an alternative to genetic testing) and relative cost of the test, 41 as well as third-party reimbursement, 38 complicate the discourse on translation of data from Pgx studies into practical recommendations.
I Zineh et al
MATERIALS AND METHODS
An electronic version of the PDR was queried to identify drugs with PIs potentially containing Pgx-related data. Since the electronic PDR is updated quarterly, all queries were conducted within a 7-day time frame (February 1-7, 2004) , recognizing that our results may be slightly different if similarly conducted at a different time point.
The following key words (in singular and plural forms) were used to initially identify potential PIs of interest: genetic; genomic; genotype; metabolizer; pharmacogenetic; pharmacogenomic; polymorphism; SNP; and variant. Once PIs were identified, duplicates (by trade name) were removed from the resultant list. Compounds available in multiple dosage forms (eg, tablets and nasal spray) were not considered duplicates, since it was presumed that prescribers would consult the PI specific to the dosage form of interest.
Using the PDR and primary Pgx literature, we then abstracted drug name, therapeutic classification, the described specific Pgx-related information in the PI, gene involved, type of gene (metabolizing, transporter, drug target), and type of polymorphism (eg, single-nucleotide polymorphism, insertion/deletion, variable number of tandem repeats). Descriptions of polymorphic drug-metabolizing phenotype in the PI, regardless of available genotype information, were considered Pgx data. For example, pharmacokinetic discussion of patients as CYP2D6 extensive, intermediate, and poor metabolizers within the PI was sufficient to include the PI for further analysis.
Where Pgx information in the PI existed, specific recommendations on Pgx-guided therapy were assessed. Pgx information was considered sufficient to guide therapy if it described: (1) specific dosing recommendations based on genotype; (2) an indication for a drug based on a molecular classification of the patient; (3) increased risk for potentially life-threatening adverse drug reactions or treatment failure, with conditional recommendations for genetic evaluation; (4) a contraindication in a genetic/phenotypic subgroup; (5) general precautionary statements and/or the need for dose reductions (without specific recommendations) based on drug-metabolizing phenotype; or (6) explicit or implicit evidence to suggest that no dose changes are necessary based on metabolizing phenotype. For these drugs, we determined whether assays are available that could facilitate genotyping of patients to aid in pharmacotherapeutic decisions.
